HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: Potential implications for the immunosurveillance of cancer

Oncogene

Volumn 28, Issue 25, 2009, Pages 2370-2382

  Lopez Soto A ^a   Folgueras, A R ^a   Seto, E ^b   Gonzalez, S ^a,c  

^a UNIVERSITY OF OVIEDO   (Spain)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

HDAC3; NKG2D; Tumour immunosurveillance; ULBPs

Indexed keywords

BINDING PROTEIN; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP3; TRICHOSTATIN A; UL16 BINDING PROTEIN; UL16 BINDING PROTEIN 1; UL16 BINDING PROTEIN 2; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEK293; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; EPIGENETICS; EPITHELIUM TUMOR; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE PROTEINS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 67649979853     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.117     Document Type: Article

References (42)

1. Ammanamanchi S, Freeman JW, Brattain MG. (2003). Acetylated sp3 is a transcriptional activator. J Biol Chem 278: 35775-35780.
2. Andresen L, Jensen H, Pedersen MT, Hansen KA, Skov S. (2007). Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. J Immunol 179: 8235-8242.
3. Andrews NC, Faller DV. (1991). A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499.
4. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M t al. (2005). Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329.
5. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. (1999). Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285: 727-729.
6. Bolden JE, Peart MJ, Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
7. Braun H, Koop R, Ertmer A, Nacht S, Suske G. (2001). Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res 29: 4994-5000.
8. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. (2001). ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133.
9. Chen L, Fischle W, Verdin E, Greene WC. (2001). Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657.
10. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U et al. (2008). NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIRHLA class I specificities. Blood 111: 1428-1436.
11. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G et al. (1999). Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19: 5504-5511.
12. Dunn GP, Old LJ, Schreiber RD. (2004a). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
13. Dunn GP, Old LJ, Schreiber RD. (2004b). The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. (2001). Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276: 35826-35835.
14. Glozak MA, Seto E. (2007). Histone deacetylases and cancer. Oncogene 26: 5420-5432. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A,
15. Lopez-Larrea C. (2008). NKG2D ligands: key targets of the immune response. Trends Immunol 29: 397-403.
16. Groh V, Wu J, Yee C, Spies T. (2002). Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature419: 734-738. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH et al. (2007). Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486.
17. Karagianni P, Wong J. (2007). HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 26: 5439-5449.
18. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M et al. (2007). Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2Dexpressing cells. Leukemia 21: 2103-2108.
19. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. (2008). Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 27: 1017-1028. Kottilil S, Shin K, Jackson JO, Reitano KN, O'Shea MA, Yang J et al. (2006). Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol 176: 1107-1114.
20. Kouzarides T. (2007). Chromatin modifications and their function. Cell 128: 693-705.
21. Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, Lopez-Vazquez A, Gonzalez S. (2008). The NKG2D receptor: sensing stressed cells. Trends Mol Med 14: 179-189. Lopez-Soto A, Quiñ ones-Lombrana A, Lopez-Arbesur, Lopez-Larrea
22. C, Gonzalez S. (2006). Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem 281: 30419-30430.
23. Luo J, Su F, Chen D, Shiloh A, Gu W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
24. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. (2003). Epigenetic targets for immune intervention in human malignancies. Oncogene 22: 6484-6488.
25. Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
26. Nausch N, Cerwenka A. (2008). NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
27. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al. (2002). Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62: 6178-6186.
28. Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz Jr S, Esteller M. (2008). Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 27: 4008-4012.
29. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. (2003). Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
30. Saunders LR, Verdin E. (2007). Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504.
31. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. (2005). Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class Irelated chain A and B. Cancer Res 65: 11136-11145.
32. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. (2005). NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-588.
33. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T. (1999). Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 59: 4266-4270.
34. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E, Davie JR. (2002). The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem 277: 35783-35786.
35. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D. (2006). ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108: 1313-1319.
36. Verdin E, Dequiedt F, Kasler HG. (2003). Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293.
37. Waldhauer I, Steinle A. (2008). NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
38. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548-13558.
39. Wooten-Blanks LG, Song P, Senkal CE, Ogretmen B. (2007). Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J 21: 3386-3397.
40. Xu WS, Parmigiani RB, Marks PA. (2007). Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
41. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. (2002). Functional domains of histone deacetylase-3. J Biol Chem 277: 9447-9454.
42. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T. (2004). Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 23: 5340-5349.